<DOC>
	<DOCNO>NCT02205814</DOCNO>
	<brief_summary>This study design double-blind , randomise , placebo-controlled , four parallel arm , dose-finding study , conduct approximately 26 site , evaluate efficacy , safety , tolerability , pharmacokinetics single intra-articular ( IA ) injection fasitibant patient symptomatic osteoarthritis ( OA ) knee . Approximately 400 male female patient 40-80 year old , BMI &lt; 30 kg/m² clinical diagnosis symptomatic primary osteoarthritis knee randomise total 4 treatment arm . Each arm include single intra-articular injection one three dosage fasitibant ( low , intermediate high dose ) OR placebo . The randomisation ratio 1:1:1:1 . The primary efficacy variable change Western Ontario McMaster Universities Visual Analogue Scale 3.1 A ( WOMAC VA 3.1 A ) ( total pain ) subscore baseline 2 week randomisation . Safety assess monitor adverse event clinical laboratory test ; local tolerability injection site also assess . In addition , population pharmacokinetics exposure-response relationship evaluate . The individual experimental clinical phase last maximal 15 week encompass 7 planned visit site , include screening , randomisation , 4 follow-up visit End study visit .</brief_summary>
	<brief_title>Fasitibant Intra-articular Injection Patients With Symptomatic Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>( 4-amino-5- ( 4- ( 4- ( 2,4-dichloro-3- ( 2,4-dimethyl-8-quinolyloxymethyl ) phenylsulfonamido ) tetrahydro-2H-4-pyranoylcarbonyl ) piperazino ) -5-oxopentyl ) ( trimethyl ) ammonium</mesh_term>
	<criteria>Male female patient age 40 80 year BMI &lt; 30 kg/m² Patient KellgrenLawrence Grade 2 3 , symptomatic primary osteoarthritis index knee ( ACR criterion ) , IA treatment indicate Pain moderate severe intensity , even treat chronic dos non steroidal antinflammatory drug History hypersensitivity/allergy drug include paracetamol disinfectant Any pharmacological treatment concomitant disease ( ) start change 4 week prior randomisation , likely change course study Use systemic topical corticosteroid &gt; 10 mg prednisolone equivalent per day , immunosuppressant drug Current use pain OA medication ( e.g . NSAIDs , COX2 inhibitor , analgesic , antidepressive agent ) , include topical treatment Viscosupplementation target knee administer &lt; 4 month prior randomisation and/or schedule course study Evidence clinically significant hepatic disease moderate severe renal insufficiency Current use medication substrate CYP3A4 and/or moderate strong CYP3A4 inhibitor Patients clinically relevant unstable disease , malignant neoplasm , opinion Investigator , may pose patient risk , confound efficacy safety result study Patients clinically relevant abnormal safety laboratory test result , and/or abnormality vital sign , and/or ECG parameter Pregnant breastfeed woman Any sign significant immunodeficiency , systemic infection , knee infection knee bursitis Patients bleed diathesis therapy anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Osteoarthritis , Knee</keyword>
	<keyword>Arthritis</keyword>
	<keyword>WOMAC</keyword>
	<keyword>Injections , intra-articular</keyword>
	<keyword>Fasitibant</keyword>
	<keyword>MEN 16132</keyword>
</DOC>